HK1079571A1 - Methods for direct detection of individual methotrexate metabolites - Google Patents

Methods for direct detection of individual methotrexate metabolites

Info

Publication number
HK1079571A1
HK1079571A1 HK06102244.4A HK06102244A HK1079571A1 HK 1079571 A1 HK1079571 A1 HK 1079571A1 HK 06102244 A HK06102244 A HK 06102244A HK 1079571 A1 HK1079571 A1 HK 1079571A1
Authority
HK
Hong Kong
Prior art keywords
mtxpg
methods
direct detection
determining
level
Prior art date
Application number
HK06102244.4A
Other languages
English (en)
Inventor
Thierry Dervieux
Russell Richerson
Original Assignee
Prometheus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Lab Inc filed Critical Prometheus Lab Inc
Publication of HK1079571A1 publication Critical patent/HK1079571A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/17Nitrogen containing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK06102244.4A 2003-03-07 2006-02-20 Methods for direct detection of individual methotrexate metabolites HK1079571A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/384,066 US6921667B2 (en) 2003-03-07 2003-03-07 Methods for direct detection of individual methotrexate metabolites
PCT/US2004/006312 WO2004081521A2 (en) 2003-03-07 2004-03-02 Methods for direct detection of individual methotrexate metabolites

Publications (1)

Publication Number Publication Date
HK1079571A1 true HK1079571A1 (en) 2006-04-07

Family

ID=32927184

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102244.4A HK1079571A1 (en) 2003-03-07 2006-02-20 Methods for direct detection of individual methotrexate metabolites

Country Status (11)

Country Link
US (1) US6921667B2 (xx)
EP (2) EP2148199A1 (xx)
JP (1) JP2006520914A (xx)
AT (1) ATE447174T1 (xx)
AU (1) AU2004219711B2 (xx)
CA (1) CA2517709C (xx)
DE (1) DE602004023824D1 (xx)
DK (1) DK1604203T3 (xx)
ES (1) ES2335767T3 (xx)
HK (1) HK1079571A1 (xx)
WO (1) WO2004081521A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563590B2 (en) * 2002-08-30 2009-07-21 Cypress Bioscience Inc. Methods of quantifying methotrexate metabolites
US7582282B2 (en) * 2003-08-29 2009-09-01 Prometheus Laboratories Inc. Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
SE0303526D0 (sv) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
US20060286571A1 (en) 2005-04-28 2006-12-21 Prometheus Laboratories, Inc. Methods of predicting methotrexate efficacy and toxicity
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
CN109689104A (zh) * 2016-08-12 2019-04-26 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
US20210052592A1 (en) * 2018-02-07 2021-02-25 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3752157A4 (en) 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
WO2019160732A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CN110320302A (zh) * 2019-07-23 2019-10-11 北京陆道培生物技术有限公司 快速测定甲氨蝶呤血药浓度的方法
CN111551659B (zh) * 2020-05-14 2022-11-18 上海大学 污水处理厂污泥中抗癌药物的快速检测分析方法
CN112415117A (zh) * 2020-12-04 2021-02-26 北京和合医学诊断技术股份有限公司 甲氨蝶呤的检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) 1950-06-20 Substituted pteridines and method
US3989703A (en) 1974-03-22 1976-11-02 Institutul Oncologic Process of preparing N[p-{[(2,4-diamino-6-pteridyl)-methyl]N10 -methylamino}-benzoyl]-glutamic acid
US4106488A (en) 1974-08-20 1978-08-15 Robert Thomas Gordon Cancer treatment method
US3892801A (en) 1974-09-11 1975-07-01 American Cyanamid Co Method for preparing alkali salts of p-methylaminobenzoylglutamic acid
US4079056A (en) 1975-03-31 1978-03-14 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making pteridine compounds
US4057548A (en) 1975-11-11 1977-11-08 Jacek Wiecko Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor
US4067867A (en) 1976-03-30 1978-01-10 Jacek Wiecko Process for preparing pyrazine precursor of methotrexate or an N-substituted derivative thereof and/or a di(lower)alkyl ester thereof
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
CH630380A5 (de) 1977-08-12 1982-06-15 Lonza Ag Verfahren zur herstellung von l-methotrexat.
US4136101A (en) 1978-02-03 1979-01-23 American Cyanamid Company Process for preparing dialkyl (p-aminobenzoyl) glutamates
US4306064A (en) 1980-03-25 1981-12-15 Ellard James A Synthesis of 2,4-diamino-6-hydroxymethylpteridine
US4421913A (en) 1980-04-23 1983-12-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Separation of triphenylphosphine oxide from methotrexate ester and purification of said ester
US4374987A (en) 1980-08-14 1983-02-22 American Cyanamid Company Process for the preparation of high purity methotrexate and derivatives thereof
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US4662359A (en) 1983-08-12 1987-05-05 Robert T. Gordon Use of magnetic susceptibility probes in the treatment of cancer
FR2590255B1 (fr) 1985-11-19 1987-12-24 Rhone Poulenc Sante Procede de preparation de derives de la pteridine
US7563590B2 (en) * 2002-08-30 2009-07-21 Cypress Bioscience Inc. Methods of quantifying methotrexate metabolites

Also Published As

Publication number Publication date
CA2517709C (en) 2011-11-15
ES2335767T3 (es) 2010-04-05
US20040175834A1 (en) 2004-09-09
EP1604203B1 (en) 2009-10-28
AU2004219711A1 (en) 2004-09-23
EP2148199A1 (en) 2010-01-27
EP1604203A4 (en) 2007-07-11
US6921667B2 (en) 2005-07-26
JP2006520914A (ja) 2006-09-14
DK1604203T3 (da) 2010-03-01
AU2004219711B2 (en) 2010-04-22
DE602004023824D1 (de) 2009-12-10
WO2004081521A2 (en) 2004-09-23
WO2004081521A3 (en) 2004-12-02
EP1604203A2 (en) 2005-12-14
CA2517709A1 (en) 2004-09-23
ATE447174T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
HK1079571A1 (en) Methods for direct detection of individual methotrexate metabolites
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드n―메틸트랜스퍼라아제의 용도
EP1415152A4 (en) METHOD, DEVICES AND COMPUTER PROGRAMS FOR VERIFYING THE INTEGRITY OF A PROBE
DE60223561D1 (de) Verfahren zum nachweis von oxidativem stress sowie kit zur durchführung davon
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE60107322D1 (de) Apparat und Methode zur Normalisung biometrischer Bewertungsmasse
WO2004021395A3 (en) Method, system, and device for performing quantitative analysis using an ftms
GB2430740A (en) System and method for tracking and quatitating chemical entites
EP1381864A4 (en) DETECTION OF CANDIDA
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
ATE408639T1 (de) Zusammensetzungen und verfahren zum oberflächeneindrücken
AU2003253440A8 (en) Method of diagnosing ovarian endometriosis
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
AU1855401A (en) Screening method for candidate drugs
TW200508605A (en) Analysis method
HUP0203408A2 (hu) Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére
DE60130970D1 (de) Reagenziensatz zur detektion von mikroorganismen, vorrichtung zur quantifizierungvon mikroorganismen und verfahren zur quantifizierung von mikroorganismen
DE60334499D1 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
DK1560929T3 (da) Polynucleotider til amplifikation og detektion af chlamydia trachomatis og neisseria gonore
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
DE602004026439D1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
TR200501974T2 (tr) Geotekstillerin tespitinde tekstil yardımcı maddesinin uygulanması yöntemi ve tertibatı.
WO2005037231A3 (en) Methods of detecting and treating facioscapulohumeral muscular dystrophy
ATE440286T1 (de) Beurteilung von nervenschäden anhand von blutproben
ATE400814T1 (de) Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180302